A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Qunibi, Wajeh ^a   Winkelmayer, Wolfgang C ^b   Solomon, Richard ^c   Moustafa, Moustafa ^d   Kessler, Paul ^e   Ho, Chiang Hong ^f   Greenberg, Jonathan ^g   Diaz Buxo, Jose A ^f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d South Carolina Nephrology and Hypertension   (United States)

^e Clinical Research Human Genome Sciences   (United States)

^f Renal Therapies Group   (United States)

^g DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BICARBONATE; CALCIUM; CALCIUM ACETATE; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; ACETIC ACID DERIVATIVE; CALCIUM DERIVATIVE; CHELATING AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NUTRITIONAL DISORDER; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; VASCULAR DISEASE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; FOLLOW UP; INTENTION TO TREAT ANALYSIS; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY;

ACETATES; CALCIUM; CALCIUM COMPOUNDS; CHELATING AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 79951557956     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-9     Document Type: Article

References (33)

1. Chronic Kidney Disease: The global challenge. AM El Nahas AK Bello, Lancet 2005 365 331 340 15664230 (Pubitemid 40139112)
2. Prevalence of Chronic Kidney Disease in the United States. J Coresh E Selvin LA Stevens J Manzi JW Kusek P Eggers F Van Lente AS Levey, JAMA 2007 298 2038 2047 10.1001/jama.298.17.2038 17986697 (Pubitemid 350074801)
3. -2000 Annual Data. United States Renal Data System, Bethesda, MD, USA 2000 http://www.USRDS.org
4. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. DS Keith GA Nichols CM Gullion JB Brown DH Smithet, Arch Intern Med 2004 164 659 663 10.1001/archinte.164.6.659 15037495 (Pubitemid 38392981)
5. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. GA Block PS Klassen JM Lazarus N Ofsthun EG Lowrie GM Chertow, J Am Soc Nephrol 2004 15 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307 (Pubitemid 39031360)
6. Phosphorus Binders and Survival on Hemodialysis. T Isakova OM Gutiérrez Y Chang A Shah H Tamez K Smith R Thadhani M Wolf, J Am Soc Nephrol 2009 20 388 396 10.1681/ASN.2008060609 19092121
7. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. T Naveh-Many R Rahamimov N Livni J Silver, J Clin Invest 1995 96 1786 1793 10.1172/JCI118224 7560070
8. Consequences of hyperphosphatemia. WY Qunibi, Kidney Int 2004 66 Suppl 90 8 12 10.1111/j.1523-1755.2004.09004.x
9. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. E Slatopolsky A Brown A and Dusso, Am J Kidney Dis 2001 37 Suppl 2 54 57 10.1053/ajkd.2001.20740
10. Pathogenesis of secondary hyperparathyroidism. E Slatopolsky A Brown A Dusso, Kidney Int 1999 56 Suppl 73 14 19 10.1046/j.1523-1755.1999.07304.x
11. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. N Voormolen M Noordzij DC Grootendorst I Beetz YW Sijpkens JG van Manen EW Boeschoten RM Huisman RT Krediet FW Dekker PREPARE study group, Nephrol Dial Transplant 2007 22 2909 2916 10.1093/ndt/gfm286 17517792 (Pubitemid 350093423)
12. Mechanisms of disease: Renal osteodystrophy. KA Hruska SL Teitelbaum, N Engl J Med 1995 333 166 175 10.1056/NEJM199507203330307 7791820
13. Association of disorders in mineral metabolism with progression of chronic kidney disease. S Schwarz BK Trivedi K Kalantar-Zadeh CP Kovesdy, Clin J Am Soc Nephrol 2006 1 825 831 10.2215/CJN.02101205 17699293
14. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). S Moe T Drüeke J Cunningham W Goodman K Martin K Olgaard S Ott S Sprague N Lameire G Eknoyan Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int 2006 69 1945 1953 10.1038/sj.ki.5000414 16641930 (Pubitemid 43924257)
15. Serum Phosphorus Levels Associate with Coronary Atherosclerosis in Young Adults. RN Foley AJ Collins CA Herzog A Ishani PA Kalra, J Am Soc Nephrol 2009 20 397 404 10.1681/ASN.2008020141 18987306
16. Phosphate regulation of vascular smooth muscle cell calcification. S Jono MD McKee CE Murry A Shioi Y Nishizawa K Mori H Morii CM Giachelli, Circ Res 2000 87 10 E17 11009570
17. Incidence and progression of coronary calcification in chronic kidney disease: The Multi-Ethnic Study of Atherosclerosis. BR Kestenbaum KL Adeney IH de Boer JH Ix MG Shlipak DS Siscovick, Kidney Int 2009 76 991 998 10.1038/ki.2009.298 19692998
18. The mechanism of phosphorus as a cardiovascular risk factor in CKD. S Mathew KS Tustison T Sugatani LR Chaudhary L Rifas KA Hruska, J Am Soc Nephrol 2008 19 1092 1105 10.1681/ASN.2007070760 18417722
19. Cardiovascular calcification in nondialyzed patients with chronic kidney disease. WY Qunibi, Semin Dial 2007 20 134 8 10.1111/j.1525-139X.2007.00260.x 17374087
20. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. JL Reynolds AJ Joannides JN Skepper R McNair LJ Schurgers D Proudfoot W Jahnen-Dechent PL Weissberg CM Shanahan, J Am Soc Nephrol 2004 15 2857 2867 10.1097/01.ASN. 0000141960.01035.28 15504939 (Pubitemid 41103395)
21. Coronary artery calcification in patients with CRF not undergoing dialysis. D Russo G Palmiero AP De Blasio MM Balletta VE Andreucci, Am J Kidney Dis 2004 44 1024 1030 10.1053/j.ajkd.2004.07.022 15558523 (Pubitemid 39556482)
22. Serum phosphate levels and mortality risk among people with chronic kidney disease. B Kestenbaum JN Sampson KD Rudser DJ Patterson SL Seliger B Young DJ Sherrard DL Andress, J Am Soc Nephrol 2005 16 520 528 10.1681/ASN.2004070602 15615819 (Pubitemid 41725150)
23. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. R Dhingra LM Sullivan CS Fox TJ Wang RB D'Agostino Sr JM Gaziano RS Vasan, Arch Intern Med 2007 167 879 885 10.1001/archinte.167.9.879 17502528 (Pubitemid 46762749)
24. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation, Am J Kidney Dis 2003 42 suppl 1 201
25. Calcium acetate control of phosphorus in hemodialysis patients. MD Sirmon WG Kirpatrick CR Nolan GW Schmitt MB Cleveland, Am J Kidney Dis 1991 17 544 550 2024656
26. Treatment of hyperphosphatemia in hemodialysis patients: The calcium acetate Renagel Evaluation (CARE Study). WY Qunibi RE Hootkins LL McDowell MS Meyer M Simon RO Garza RW Pelham MV Cleveland LR Muenz DY He CR Nolan, Kidney Int 2004 65 1914 1926 10.1111/j.1523-1755.2004.00590.x 15086935 (Pubitemid 38591044)
27. Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. M Wallot KE Bonzel A Winter B Georger B Lettgen M Bald, Pediatr Nephrol 1996 10 625 30 10.1007/s004670050175 8897570 (Pubitemid 26331777)
28. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. K Kalantar-Zadeh R Mehrotra D Fouque JD Kopple, Semin Dial 2004 17 455 465 10.1111/j.0894-0959.2004.17606.x 15660576 (Pubitemid 40110431)
29. The role of metabolic acidosis in the pathogenesis of renal osteodystrophy. JA Kraut, Adv Ren Replace Ther 1995 2 40 51 7614335
30. A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis. J Borrego P Pérez del Barrio P Serrano MJ García Cortés MC Snchez Perales FJ Borrego A Liébana JM Gil Cunquero V Pérez Bãasco, Nefrologia 2000 20 348 54 11039260
31. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. M Ketteler M Rix S Fan N Pritchard O Oestergaard S Chasan-Taber J Heaton A Duggal PA Kalra, Clin J Am Soc Nephrol 2008 3 1125 1130 10.2215/CJN.05161107 18450923
32. Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4: A Randomized Trial. SM Sprague H Abboud P Qiu M Dauphin P Zhang W Finn, Clin J Am Soc Nephrol 2009 4 178 185 10.2215/CJN.02830608 19056618
33. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. D Russo I Miranda C Ruocco Y Battaglia E Buonanno S Manzi L Russo A Scafarto VE Andreucci, Kidney Int 2007 72 1255 1261 10.1038/sj.ki.5002518 17805238 (Pubitemid 350059663)